Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade

Cancer Immunology Research

Volumn 5, Issue 6, 2017, Pages 480-492

  Zhou, Jun ^a   Mahoney, Kathleen M ^a,b   Giobbie Hurder, Anita ^a   Zhao, Fengmin ^a   Lee, Sandra ^a   Liao, Xiaoyun ^a,c   Rodig, Scott ^a,c   Li, Jingjing ^a   Wu, Xinqi ^a   Butterfield, Lisa H ^d,e   Piesche, Matthias ^a,f   Manos, Michael P ^a   Eastman, Lauren M ^a   Dranoff, Glenn ^g   Freeman, Gordon J ^a   Hodi, F Stephen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IPILIMUMAB; PROGRAMMED DEATH 1 LIGAND 1; SARGRAMOSTIM; TUMOR NECROSIS FACTOR; VEMURAFENIB; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOKINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; ISOPROTEIN; MONOCLONAL ANTIBODY; PEMBROLIZUMAB; TUMOR MARKER;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DAMAGE; CELL DEATH; CELL PROLIFERATION; CELL STRESS; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOGLOBULIN DOMAIN; LIMIT OF DETECTION; MELANOMA; MELANOMA CELL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; STOP CODON; SUPERNATANT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; GENETICS; METABOLISM; PHASE 1 CLINICAL TRIAL; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7-H1 ANTIGEN; BEVACIZUMAB; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CTLA-4 ANTIGEN; CYTOKINES; HUMANS; IPILIMUMAB; MELANOMA; PROTEIN ISOFORMS;

EID: 85020673929     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0329     Document Type: Article

References (45)

1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008;26:677-704.
2. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-26.
3. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9.
4. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCGinduced granulomata: Associations with localized stage progression. Cancer 2007;109:1499-505.
5. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-65.
6. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007;121:751-8.
7. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren, H, van Boven, H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011;117:2192-201.
8. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-66.
9. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19: 3462-73.
10. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007; 19:1223-34.
11. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4 CD25(Hi) regulatory T cells. Int Immunol 2009;21:1065-77.
12. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
14. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
15. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al.MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62.
16. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibodyMPDL3280A in cancer patients. Nature 2014;515:563-7.
17. Wang L, Wang H, Chen H, Wang WD, Chen XQ, Geng QR, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget 2015;6: 41228-36.
18. Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 2011;17:1915-23.
19. Rossille D, GressierM, Damotte D, Maucort-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014;28: 2367-75.
20. Frigola X, Inman BA, Krco CJ, Liu X, Harrington SM, Bulur PA, et al. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol Lett 2012;142:78-82.
21. He XH, Xu LH, Liu Y. Identification of a novel splice variant of human PDL1 mRNA encoding an isoform-lacking Igv-like domain. Acta pharmacologica Sinica 2005;26:462-8.
22. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2:632-42.
23. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA 2014;312: 1744-53.
24. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Analys 1999;30:253-70.
25. Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003;100:3398-403.
26. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
27. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase iii trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-94.
28. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.NEngl JMed 2015;373:1270-71.
29. Venables JP.Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54.
30. Tang W, Gunn TM, McLaughlin DF, Barsh GS, Schlossman SF, Duke-Cohan JS. Secreted and membrane attractin result from alternative splicing of the human ATRN gene. Proc Natl Acad Sci U S A 2000;97:6025-30.
31. Gower HJ, Barton CH, Elsom VL, Thompson J, Moore SE, Dickson G, et al. Alternative splicing generates a secreted form of N-CAM in muscle and brain. Cell 1988;55:955-64.
32. van der Voort, R, Verweij V, de Witte, TM, Lasonder E, Adema GJ, Dolstra H. An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6 cells. J Leukoc Biol 2010;87: 1029-39.
33. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278-88.
34. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 2002;87:245-54.
35. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
36. Dranoff G.Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
37. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-67.
38. Chada S, Ramesh R, Mhashilkar AM. Cytokine- And chemokine-based gene therapy for cancer. Curr Opin Mol Thera 2003;5:463-74.
39. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800.
40. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013;19:1363-74.
41. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gammainduced upregulation of B7-H1 (CD274). FEBS Lett 2006;580:755-62.
42. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110: 296-304.
43. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Upregulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8() T cells. Sci TranslatMed 2013;5:200ra116.
44. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
45. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.